Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H2R and D3R

Even today, the role of the histamine H₂ receptor (H₂R) in the central nervous system (CNS) is widely unknown. In previous research, many dimeric, high-affinity and subtype-selective carbamoylguanidine-type ligands such as UR-NK22 (5, pK_i = 8.07) were reported as H₂R agonists. However, their applicability to the study of the H₂R in the CNS is compromised by their molecular and pharmacokinetic properties, such as high molecular weight and, consequently, a limited bioavailability. To address the need for more drug-like H₂R agonists with high affinity, we synthesized a series of monomeric (thio)carbamoylguanidine-type ligands containing various spacers and side-chain moieties. This structural simplification resulted in potent (partial) agonists (guinea pig right atrium, [³⁵S]GTPγS and β-arrestin2 recruitment assays) with human (h) H₂R affinities in the one-digit nanomolar range (pK_i (139, UR-KAT523): 8.35; pK_i (157, UR-MB-69): 8.69). Most of the compounds presented here exhibited an excellent selectivity profile towards the hH₂R, e.g. 157 being at least 3800-fold selective within the histamine receptor family. The structural similarities of our monomeric ligands to pramipexole (6), a dopamine receptor agonist, suggested an investigation of the binding behavior at those receptors. The target compounds were (partial) agonists with moderate affinity at the hD_2longR and agonists with high affinity at the hD₃R (e.g. pK_i (139, UR-KAT523): 7.80; pK_i (157, UR-MB-69): 8.06). In summary, we developed a series of novel, more drug-like H₂R and D₃R agonists for the application in recombinant systems in which either the H₂R or the D₃R is solely expressed. Furthermore, our ligands are promising lead compounds in the development of selective H₂R agonists for future in vivo studies or experiments utilizing primary tissue to unravel the role and function of the H₂R in the CNS.

Dimeric carbamoylguanidine-type histamine H2 receptor ligands: A new class of potent and selective agonists

The bioisosteric replacement of the acylguanidine moieties in dimeric histamine H2 receptor (H2R) agonists by carbamoylguanidine groups resulted in compounds with retained potencies and intrinsic activities, but considerably improved stability against hydrolytic cleavage. These compounds achieved up to 2500 times the potency of histamine when studied in [(35)S]GTPγS assays on recombinant human and guinea pig H2R. Unlike 3-(imidazol-4-yl)propyl substituted carbamoylguanidines, the corresponding 2-amino-4-methylthiazoles revealed selectivity over histamine receptor subtypes H1R, H3R and H4R in radioligand competition binding studies. H2R binding studies with three fluorescent compounds and one tritium-labeled ligand, synthesized from a chain-branched precursor, failed due to pronounced cellular accumulation and high non-specific binding. However, the dimeric H2R agonists proved to be useful pharmacological tools for functional studies on native cells, as demonstrated for selected compounds by cAMP accumulation and inhibition of fMLP-stimulated generation of reactive oxygen species in human monocytes.